Literature DB >> 1687923

Beta-adrenergic blockade in dilated cardiomyopathy, ischemic cardiomyopathy, and other secondary cardiomyopathies.

F Waagstein1.   

Abstract

Beta-blockers were initially given to patients with chronic heart failure due to ischemic heart disease and resting tachycardia. The prompt effect on severe backward heart failure was directly associated with an immediate fall in heart rate. This observation led to long-term administration to patients with idiopathic dilated cardiomyopathy and, later, to patients with ischemic cardiomyopathy and secondary cardiomyopathies as well. Due to marked down-regulation of beta receptors, patients with heart failure are extremely sensitive to beta blockade. A test dose of metoprolol 5 mg b.i.d. for 2 days is recommended to select patients for long-term beta-blockade, followed by careful titration with increment in dose over 6 weeks. One important effect of beta-blockade in the early phase of treatment is a reduction in the myocardial energy demand early after the onset of long-term treatment. After 1 month of treatment with beta-blockers, marked improvement of diastolic function is observed. This effect might be attributed to inhibition of calcium overload. After 3 months of treatment, an increase in ejection fraction can be observed, which might be attributed to upregulation of beta receptors. The withdrawal of long-term treatment was followed by a deterioration of heart function in 61% of patients and improvement was seen after reinstitution of beta-blockade. There was an increase in cardiac index and stroke work index at rest as well as during supine exercise. A marked fall in left ventricular filling pressure at rest and unchanged filling pressure during supine exercise was noted, while exercise capacity increased by 25%. A similar pattern was seen in patients with ischemic cardiomyopathies and other secondary cardiomyopathies. However, the increase in ejection fraction in the ischemic cardiomyopathy group was lower (0.06) compared to the groups with dilated cardiomyopathy and other secondary cardiomyopathies (0.18).

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1687923     DOI: 10.1007/bf01752532

Source DB:  PubMed          Journal:  Heart Vessels Suppl        ISSN: 0935-736X


  14 in total

Review 1.  Therapy of idiopathic dilated cardiomyopathy with chronic beta-adrenergic blockade.

Authors:  E M Gilbert; J B O'Connell; M R Bristow
Journal:  Heart Vessels Suppl       Date:  1991

2.  Antibodies to the ADP/ATP carrier, an autoantigen in myocarditis and dilated cardiomyopathy, penetrate into myocardial cells and disturb energy metabolism in vivo.

Authors:  K Schulze; B F Becker; H P Schultheiss
Journal:  Circ Res       Date:  1989-02       Impact factor: 17.367

3.  Homologous desensitization of beta-adrenergic receptor coupled adenylate cyclase. Resensitization by polyethylene glycol treatment.

Authors:  R H Strasser; R J Lefkowitz
Journal:  J Biol Chem       Date:  1985-04-25       Impact factor: 5.157

4.  Apex cardiogram and systolic time intervals in acute myocardial infarction and effects of practolol.

Authors:  F Waagstein; A C Hjalmarson; H S Wasir
Journal:  Br Heart J       Date:  1974-11

5.  Double-blind trial of chronic oral beta blockade in congestive cardiomyopathy.

Authors:  H Ikram; D Fitzpatrick
Journal:  Lancet       Date:  1981-09-05       Impact factor: 79.321

6.  Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy.

Authors:  F Waagstein; A Hjalmarson; E Varnauskas; I Wallentin
Journal:  Br Heart J       Date:  1975-10

7.  Long-term beta-blockade in dilated cardiomyopathy. Effects of short- and long-term metoprolol treatment followed by withdrawal and readministration of metoprolol.

Authors:  F Waagstein; K Caidahl; I Wallentin; C H Bergh; A Hjalmarson
Journal:  Circulation       Date:  1989-09       Impact factor: 29.690

8.  Oral beta-adrenergic blockade with metoprolol in chronic severe dilated cardiomyopathy.

Authors:  P J Currie; M J Kelly; A McKenzie; R W Harper; Y L Lim; J Federman; S T Anderson; A Pitt
Journal:  J Am Coll Cardiol       Date:  1984-01       Impact factor: 24.094

9.  Abnormal intracellular calcium handling in myocardium from patients with end-stage heart failure.

Authors:  J K Gwathmey; L Copelas; R MacKinnon; F J Schoen; M D Feldman; W Grossman; J P Morgan
Journal:  Circ Res       Date:  1987-07       Impact factor: 17.367

10.  Beneficial effects of long-term beta-blockade in congestive cardiomyopathy.

Authors:  K Swedberg; A Hjalmarson; F Waagstein; I Wallentin
Journal:  Br Heart J       Date:  1980-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.